Category Archives: BioCubaFarma COVID-19 battle

Cuba readies 100 million doses of anti-COVID vaccine

Cuba readies 100 million doses of anti-COVID vaccine
Finlay Vaccine Institute director, Dr. Vicente Vérez Bencomo, reports that Cuba is creating capacity to produce 100 million doses of the Soberana 02 vaccine

Miguel Febles Hernándezjanuary 22, 2021 08:01:51


Photo: ACN
The general director of the Finlay Vaccine Institute, Vicente Vérez Bencomo, announced, at a press conference with accredited foreign agencies in attendance, that Cuba is creating capacity to produce 100 million doses of the Soberana 02 injectable vaccine against COVID-19.

He reiterated that the objective is to satisfy the needs of the country and also those of other nations interested in acquiring the vaccine, which thus far include Vietnam, Iran, Venezuela, Pakistan and India. In the case of our country, he clarified, administration will be free of cost, with the intention of immunizing the entire population this year.

“Cuba’s strategy to market the vaccine has a combined goal of serving humanity and impacting global health. We are not a multinational, with the financial objective as the number one motivation. Our aim is to create more health,” said Vérez Bencomo, Prensa Latina reported.

The Soberana 02 vaccine began extended Phase II clinical trials this week, increasing participation to 900 volunteers between 19 and 80 years of age, while in February a new investigation with the pediatric population will be conducted.

Dr. Vérez explained that after the results of this stage are analyzed, a third phase will follow. During this period, health authorities plan to include 150,000 at persons in vulnerable groups and residents of high-risk areas.

BioCubaFarma in the COVID-19 battle

BioCubaFarma in the COVID-19 battle
To learn about progress being made in scientific research to identify new products to treat COVID-19, Granma interviews Dr. Eduardo Martínez Díaz, president of BioCubaFarma Enterprise Group

Author: Orfilio Peláez | informacion@granmai.cu
april 15, 2020 10:04:11

f0026755

 

 

 

 

 

 

Photo: Ricardo López Hevia
To learn about progress being made in scientific research to identify new products to treat COVID-19, Granma interviews Dr. Eduardo Martínez Díaz, president of the BioCubaFarma Enterprise Group:

-What has the Cuban biotechnology and pharmaceutical industry been doing to confront COVID-19?

-Our Enterprise Group has a specific plan with four fundamental components which are

*Supply medicines included in the COVID-19treatment protocol established by the Ministry of Public Health (Minsap).

*Research and development to provide new products and knowledge to combat this virus

*Cooperation with other countries in supplying drugs to fight the pandemic

*Take steps internally within our companies to protect workers and guarantee operations under current circumstances

-How many products does BioCubaFarma currently provide for Cuba’s COVID-19 treatment protocol?

-At the beginning, 22 medicines were identified, several anti-virals, primarily Interferon, and an important group of drugs for hospital use with patients in different phases, including those in serious and critical condition. We currently have stocks of these for thousands of patients and continue to expand production capacity.

BioCubaFarma companies have added production of face masks and sanitizing products such as medicinal soaps, hypochlorite solution, hydroalcoholic solutions, etc. Continue reading BioCubaFarma in the COVID-19 battle